{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:31:14Z","timestamp":1792794674370,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2016-75197-R"],"award-info":[{"award-number":["SAF2016-75197-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Government of Castile and Le\u00f3n","doi-asserted-by":"publisher","award":["SA113P23"],"award-info":[{"award-number":["SA113P23"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["BOE-B-2017-72875"],"award-info":[{"award-number":["BOE-B-2017-72875"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Spanish Association Against Cancer Scientific Foundation","doi-asserted-by":"publisher","award":["IGTP-AECC_2022-042\/PRYCO223102ARME"],"award-info":[{"award-number":["IGTP-AECC_2022-042\/PRYCO223102ARME"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Biomedical Research Network Center of Hepatic and Digestive Diseases","doi-asserted-by":"publisher","award":["EHD22PI01"],"award-info":[{"award-number":["EHD22PI01"]}],"id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Biomedical Research Network Center of Hepatic and Digestive Diseases","doi-asserted-by":"publisher","award":["CB06\/04\/0023"],"award-info":[{"award-number":["CB06\/04\/0023"]}],"id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Asuntos Econ\u00f3micos y Transformaci\u00f3n Digital, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bcp.2025.116914","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T20:35:30Z","timestamp":1743712530000},"page":"116914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Relevance of transportome among the mechanisms of chemoresistance in hepatoblastoma"],"prefix":"10.1016","volume":"237","author":[{"given":"Candela","family":"Cives-Losada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitane","family":"Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Chinchilla-T\u00e1bora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Manuela","family":"Barranco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro del","family":"R\u00edo-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luz","family":"Martinez-Chantar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias A.","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.G.","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-0326","authenticated-orcid":false,"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2025.116914_b0005","first-page":"62","article-title":"Incidence trends and survival prediction of hepatoblastoma in children: a population-based study","volume":"39","author":"Feng","year":"2019","journal-title":"Cancer Commun. (Lond)"},{"issue":"4","key":"10.1016\/j.bcp.2025.116914_b0010","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cld.2018.06.008","article-title":"Pediatric liver tumors","volume":"22","author":"Ng","year":"2018","journal-title":"Clin. Liver Dis."},{"issue":"2","key":"10.1016\/j.bcp.2025.116914_b0015","article-title":"Pediatric primary hepatic tumors: diagnostic considerations","volume":"11","author":"Lucas","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.bcp.2025.116914_b0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.21037\/tgh.2019.12.03","article-title":"Hepatoblastoma: current knowledge and promises from preclinical studies","volume":"5","author":"Calvisi","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.bcp.2025.116914_b0025","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","article-title":"Hepatic stem-like phenotype and interplay of Wnt\/beta-catenin and Myc signaling in aggressive childhood liver cancer","volume":"14","author":"Cairo","year":"2008","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.116914_b0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/hep.29672","article-title":"New insights into diagnosis and therapeutic options for proliferative hepatoblastoma","volume":"68","author":"Hooks","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bcp.2025.116914_b0035","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jhep.2020.03.025","article-title":"Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications","volume":"73","author":"Carrillo-Reixach","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.bcp.2025.116914_b0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","article-title":"Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children\u2019s Hepatic tumors International Collaboration","volume":"18","author":"Meyers","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.116914_b0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0971-9261.142001","article-title":"The treatment of hepatoblastoma: its evolution and the current status as per the SIOPEL trials","volume":"19","author":"Aronson","year":"2014","journal-title":"J. Indian Assoc. Pediatr. Surg."},{"key":"10.1016\/j.bcp.2025.116914_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121944","article-title":"Surgical management of hepatoblastoma and recent advances","volume":"11","author":"Yang","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2025.116914_b0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bjs.9681","article-title":"Effect of neoadjuvant chemotherapy on resectability of stage III and IV hepatoblastoma","volume":"102","author":"Venkatramani","year":"2015","journal-title":"Br. J. Surg."},{"issue":"1","key":"10.1016\/j.bcp.2025.116914_b0060","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2741\/e393","article-title":"Activation of Wnt and Myc signaling in hepatoblastoma","volume":"4","author":"Cairo","year":"2012","journal-title":"Front. Biosci. (Elite Ed.)"},{"key":"10.1016\/j.bcp.2025.116914_b0065","first-page":"1","article-title":"Unresectable hepatoblastoma: current perspectives","volume":"9","author":"Trobaugh-Lotrario","year":"2017","journal-title":"Hepat. Med."},{"issue":"7","key":"10.1016\/j.bcp.2025.116914_b0070","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1097\/MPH.0000000000001544","article-title":"Sustained remission after maintenance irinotecan in patient with multiply relapsed hepatoblastoma","volume":"42","author":"Natarajan","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2025.116914_b0075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2020.09.026","article-title":"A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients","volume":"141","author":"Cairo","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2025.116914_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030407","article-title":"Mechanisms of anticancer drug resistance in hepatoblastoma","volume":"11","author":"Marin","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bcp.2025.116914_b0085","doi-asserted-by":"crossref","first-page":"402","DOI":"10.2174\/156800912800190875","article-title":"Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs","volume":"12","author":"Marin","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bcp.2025.116914_b0090","doi-asserted-by":"crossref","first-page":"15424","DOI":"10.1038\/ncomms15424","article-title":"Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies","volume":"8","author":"San Jose-Eneriz","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116914_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115209","article-title":"Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells","volume":"165","author":"Sanchez-Martin","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.bcp.2025.116914_b0100","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jhep.2023.05.031","article-title":"Identification and experimental validation of druggable epigenetic targets in hepatoblastoma","volume":"79","author":"Claveria-Cabello","year":"2023","journal-title":"J. Hepatol."},{"issue":"35","key":"10.1016\/j.bcp.2025.116914_b0105","doi-asserted-by":"crossref","first-page":"12853","DOI":"10.1073\/pnas.1407358111","article-title":"(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells","volume":"111","author":"Barsyte-Lovejoy","year":"2014","journal-title":"PNAS"},{"issue":"14","key":"10.1016\/j.bcp.2025.116914_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143524","article-title":"Expression of chemoresistance-associated ABC proteins in hepatobiliary, pancreatic and gastrointestinal cancers","volume":"14","author":"Marin","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bcp.2025.116914_b0115","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/mp300028a","article-title":"No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors","volume":"9","author":"Martinez-Becerra","year":"2012","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.bcp.2025.116914_b0120","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/hep.26425","article-title":"Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib","volume":"58","author":"Herraez","year":"2013","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.bcp.2025.116914_b0125","doi-asserted-by":"crossref","first-page":"15846","DOI":"10.18632\/oncotarget.15029","article-title":"The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma","volume":"8","author":"Geier","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.116914_b0130","first-page":"27","article-title":"Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy","volume":"7","author":"Marin","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bcp.2025.116914_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114542","article-title":"Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update","volume":"239","author":"Engle","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.116914_b0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<95::AID-IJC15>3.0.CO;2-G","article-title":"Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer","volume":"86","author":"Oguri","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2025.116914_b0145","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.2005.01.6196","article-title":"Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma","volume":"24","author":"Haber","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2025.116914_b0150","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1111\/j.1582-4934.2010.01117.x","article-title":"Molecular markers in circulating tumour cells from metastatic colorectal cancer patients","volume":"14","author":"Gazzaniga","year":"2010","journal-title":"J. Cell Mol. Med."},{"issue":"8","key":"10.1016\/j.bcp.2025.116914_b0155","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/cncr.10858","article-title":"The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model","volume":"95","author":"Warmann","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2025.116914_b0160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jpedsurg.2008.10.088","article-title":"Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies","volume":"44","author":"Oue","year":"2009","journal-title":"J. Pediatr. Surg."},{"issue":"11","key":"10.1016\/j.bcp.2025.116914_b0165","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1872-034X.2008.00381.x","article-title":"Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: a study in patients and in vitro","volume":"38","author":"Vander Borght","year":"2008","journal-title":"Hepatol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.116914_b0170","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2008.07.014","article-title":"Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy","volume":"64","author":"Ota","year":"2009","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2025.116914_b0175","first-page":"1098","article-title":"Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein","volume":"20","author":"Liu","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.116914_b0180","first-page":"965","article-title":"Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma","volume":"23","author":"Korita","year":"2010","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2025.116914_b0185","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0026-895X(24)23190-4","article-title":"Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells","volume":"55","author":"Cui","year":"1999","journal-title":"Mol. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2025.116914_b0190","doi-asserted-by":"crossref","first-page":"24706","DOI":"10.3390\/ijms141224706","article-title":"Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma","volume":"14","author":"Alisi","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2025.116914_b0195","first-page":"2790","article-title":"Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy","volume":"8","author":"Su","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"5","key":"10.1016\/j.bcp.2025.116914_b0200","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/08880010590964192","article-title":"Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma","volume":"22","author":"Warmann","year":"2005","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2025.116914_b0205","first-page":"989","article-title":"Glutathione S\u2011transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer","volume":"41","author":"Zou","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2025.116914_b0210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fphar.2013.00089","article-title":"Mechanisms regulating resistance to inhibitors of topoisomerase II","volume":"4","author":"Ganapathi","year":"2013","journal-title":"Front. Pharmacol."},{"issue":"4C","key":"10.1016\/j.bcp.2025.116914_b0215","first-page":"3127","article-title":"Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin","volume":"18","author":"Bader","year":"1998","journal-title":"Anticancer Res."},{"issue":"47","key":"10.1016\/j.bcp.2025.116914_b0220","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bcp.2025.116914_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166780","article-title":"SETD7 promotes metastasis of triple-negative breast cancer by YY1 lysine methylation","volume":"1869","author":"Gao","year":"2023","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"12","key":"10.1016\/j.bcp.2025.116914_b0230","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.7150\/ijbs.87182","article-title":"Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3\/PD-L1 cascade","volume":"19","author":"Lv","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.116914_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040519","article-title":"Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line resistant to gemcitabine","volume":"11","author":"Varamo","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2025.116914_b0240","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1038\/s41598-021-85289-0","article-title":"PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma","volume":"11","author":"Marayati","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.116914_b0245","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pedn.2017.06.015","article-title":"The efficacy of art therapy in pediatric oncology patients: an integrative literature review","volume":"36","author":"Aguilar","year":"2017","journal-title":"J. Pediatr. Nurs."},{"key":"10.1016\/j.bcp.2025.116914_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102221","article-title":"Cabozantinib: an evolving therapy for hepatocellular carcinoma","volume":"98","author":"El-Khoueiry","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2025.116914_b0255","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1756-9966-30-96","article-title":"HGF\/c-Met related activation of \u03b2-catenin in hepatoblastoma","volume":"30","author":"Purcell","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:23:53Z","timestamp":1762097033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225001765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":51,"alternative-id":["S0006295225001765"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116914","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relevance of transportome among the mechanisms of chemoresistance in hepatoblastoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116914"}}